CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid‑in Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balances (in shares) at Dec. 31, 2023		33,437,296
Beginning balances at Dec. 31, 2023	$ 242,360	$ 3	$ 437,132	$ 195	$ (194,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		30,888
Issuance of common stock upon exercise of stock options	206		206
Vesting of early exercised options (in shares)		3,411
Vesting of early exercised options	13		13
Vesting of restricted stock units (in shares)		132,458
Stock‑based compensation	3,733		3,733
Other comprehensive income (loss)	(441)			(441)
Net (loss) income	23,496				23,496
Ending balances (in shares) at Mar. 31, 2024		33,604,053
Ending balances at Mar. 31, 2024	269,367	$ 3	441,084	(246)	(171,474)
Beginning balances (in shares) at Dec. 31, 2023		33,437,296
Beginning balances at Dec. 31, 2023	242,360	$ 3	437,132	195	(194,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Other comprehensive income (loss)	777
Net (loss) income	64,495
Ending balances (in shares) at Sep. 30, 2024		37,400,499
Ending balances at Sep. 30, 2024	422,447	$ 4	551,946	972	(130,475)
Beginning balances (in shares) at Dec. 31, 2023		33,437,296
Beginning balances at Dec. 31, 2023	$ 242,360	$ 3	437,132	195	(194,970)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Vesting of early exercised options (in shares)	1,676
Ending balances (in shares) at Dec. 31, 2024	37,574,538	37,574,538
Ending balances at Dec. 31, 2024	$ 428,678	$ 4	558,061	(43)	(129,344)
Beginning balances (in shares) at Mar. 31, 2024		33,604,053
Beginning balances at Mar. 31, 2024	269,367	$ 3	441,084	(246)	(171,474)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		166,155
Issuance of common stock upon exercise of stock options	1,104		1,104
Vesting of early exercised options (in shares)		3,411
Vesting of early exercised options	13		13
Vesting of restricted stock units (in shares)		11,490
Purchase of common stock under the employee stock purchase plan (in shares)		20,384
Purchase of common stock under the employee stock purchase plan	263		263
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs of $392 (in shares)		3,367,003
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs of $392	99,608	$ 1	99,607
Stock‑based compensation	4,622		4,622
Other comprehensive income (loss)	(83)			(83)
Net (loss) income	55,031				55,031
Ending balances (in shares) at Jun. 30, 2024		37,172,496
Ending balances at Jun. 30, 2024	429,925	$ 4	546,693	(329)	(116,443)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		63,228
Issuance of common stock upon exercise of stock options	381		381
Vesting of early exercised options (in shares)		3,253
Vesting of early exercised options	12		12
Vesting of restricted stock units (in shares)		161,522
Stock‑based compensation	4,860		4,860
Other comprehensive income (loss)	1,301			1,301
Net (loss) income	(14,032)				(14,032)
Ending balances (in shares) at Sep. 30, 2024		37,400,499
Ending balances at Sep. 30, 2024	$ 422,447	$ 4	551,946	972	(130,475)
Beginning balances (in shares) at Dec. 31, 2024	37,574,538	37,574,538
Beginning balances at Dec. 31, 2024	$ 428,678	$ 4	558,061	(43)	(129,344)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		40,984
Issuance of common stock upon exercise of stock options	350		350
Vesting of early exercised options (in shares)		1,676
Vesting of early exercised options	14		14
Vesting of restricted stock units (in shares)		325,085
Stock‑based compensation	5,087		5,087
Other comprehensive income (loss)	480			480
Net (loss) income	(17,349)				(17,349)
Ending balances (in shares) at Mar. 31, 2025		37,942,283
Ending balances at Mar. 31, 2025	$ 417,260	$ 4	563,512	437	(146,693)
Beginning balances (in shares) at Dec. 31, 2024	37,574,538	37,574,538
Beginning balances at Dec. 31, 2024	$ 428,678	$ 4	558,061	(43)	(129,344)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	56,199
Vesting of early exercised options (in shares)	0
Other comprehensive income (loss)	$ 664
Net (loss) income	$ (104,586)
Ending balances (in shares) at Sep. 30, 2025	38,219,232	38,219,232
Ending balances at Sep. 30, 2025	$ 340,716	$ 4	574,021	621	(233,930)
Beginning balances (in shares) at Mar. 31, 2025		37,942,283
Beginning balances at Mar. 31, 2025	417,260	$ 4	563,512	437	(146,693)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		12,106
Issuance of common stock upon exercise of stock options	20		20
Vesting of restricted stock units (in shares)		29,163
Purchase of common stock under the employee stock purchase plan (in shares)		50,418
Purchase of common stock under the employee stock purchase plan	317		317
Stock‑based compensation	5,048		5,048
Other comprehensive income (loss)	(37)			(37)
Net (loss) income	(43,103)				(43,103)
Ending balances (in shares) at Jun. 30, 2025		38,033,970
Ending balances at Jun. 30, 2025	379,505	$ 4	568,897	400	(189,796)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		3,109
Issuance of common stock upon exercise of stock options	8		8
Vesting of restricted stock units (in shares)		182,153
Stock‑based compensation	5,116		5,116
Other comprehensive income (loss)	221			221
Net (loss) income	$ (44,134)				(44,134)
Ending balances (in shares) at Sep. 30, 2025	38,219,232	38,219,232
Ending balances at Sep. 30, 2025	$ 340,716	$ 4	$ 574,021	$ 621	$ (233,930)